Who are cefepime/AAI101 combination's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zavicefta, Ceftazidime-Avibactam, Fosfomycin and imipenem, Sulopenem Etzadroxil/Probenecid, Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol, Amoxil, Bicillin C-R.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cefepime-aai101-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

cefepime/AAI101 combination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

cefepime/AAI101 combination (cefepime/AAI101 combination) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: beta-lactam antibiotic. Area: Infectious Diseases.

phase 3 beta-lactam antibiotic bacterial cell wall synthesis Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

cefepime/AAI101 combination (cefepime/AAI101 combination) — Allecra. Cefepime/AAI101 combination is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
cefepime/AAI101 combination TARGET	cefepime/AAI101 combination	Allecra	phase 3	beta-lactam antibiotic	bacterial cell wall synthesis
Zavicefta, Ceftazidime-Avibactam	zavicefta-ceftazidime-avibactam	Pfizer	marketed	Cephalosporin antibiotic and beta-lactamase inhibitor combination	Bacterial cell wall synthesis
Fosfomycin and imipenem	Fosfomycin and imipenem	Juan A. Arnaiz	marketed	Beta-lactam antibiotic combination	Bacterial cell wall synthesis (MurA enzyme and penicillin-binding proteins)
Sulopenem Etzadroxil/Probenecid	Sulopenem Etzadroxil/Probenecid	Iterum Therapeutics, International Limited	phase 3	carbapenem antibiotic	bacterial cell wall synthesis
Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol	Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol	Tuberculosis Research Centre, India	phase 3	Anti-tuberculosis combination therapy	Multiple: DNA gyrase (moxifloxacin), mycobacterial cell wall synthesis (isoniazid, ethambutol), RNA polymerase (rifampicin), bacterial metabolism (pyrazinamide)
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	marketed	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01
Bicillin C-R	Penicillin G Benzathine	Pfizer	marketed	Beta-lactam antibiotic	Cell-wall peptidoglycan biosynthesis	1952-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-12-08 — Amoxil · 8778924 · Compound · US
2026-12-08 — Amoxil · 8357394 · Formulation · US
2027-05-07 — Amoxil · 8299052 · Method of Use · US

Sponsor landscape (beta-lactam antibiotic class)

Allecra · 1 drug in this class
Qilu Hospital of Shandong University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). cefepime/AAI101 combination — Competitive Intelligence Brief. https://druglandscape.com/ci/cefepime-aai101-combination. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing